← Database
M&A

IONISOS

Acquired by

3I

FRANCE Life Sciences EV [100m EUR - 500m EUR] 07/2019

Target

IONISOS

Acquirer

3I

Context

Ionisos, a leading European specialist in cold sterilization services, has entered its fifth LBO cycle following its acquisition by 3i Infrastructure. The London-listed investor is deploying �220 million to acquire up to 100% of the company's equity from Ardian Expansion, which had held the asset since 2016. The remaining shares are held by the management team.

IONISOS, which reported an EBITDA margin of LOGIN in 2016, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.4x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

IONISOS, a specialist in gamma sterilization, ebeam, X-rays and ethylene oxide sterilization, offers its ionizing radiation and EO gas treatment services to professionals in the medical, pharmaceutical, veterinary, cosmetics and agri-food packaging industries.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2016
LOGIN
LOGIN
LOGIN
2015
LOGIN
LOGIN
LOGIN

Other operations with IONISOS

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.